PL393385A1 - Sposób modyfikacji i rekrystalizacji pokroju kryształów substancji leczniczej, kryształy mykofenolanu sodu i ich zastosowanie oraz kompozycja farmaceutyczna - Google Patents

Sposób modyfikacji i rekrystalizacji pokroju kryształów substancji leczniczej, kryształy mykofenolanu sodu i ich zastosowanie oraz kompozycja farmaceutyczna

Info

Publication number
PL393385A1
PL393385A1 PL393385A PL39338504A PL393385A1 PL 393385 A1 PL393385 A1 PL 393385A1 PL 393385 A PL393385 A PL 393385A PL 39338504 A PL39338504 A PL 39338504A PL 393385 A1 PL393385 A1 PL 393385A1
Authority
PL
Poland
Prior art keywords
habit
recrystallization
modification
pharmaceutical composition
drug substance
Prior art date
Application number
PL393385A
Other languages
English (en)
Other versions
PL213192B1 (pl
Inventor
Sabine Pfeffer
Dierk Wieckhusen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9951448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL393385(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL393385A1 publication Critical patent/PL393385A1/pl
Publication of PL213192B1 publication Critical patent/PL213192B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PL393385A 2003-01-20 2004-01-19 Sposób modyfikacji pokroju krysztalów substancji leczniczej, krysztaly mykofenolanu sodu i ich zastosowanie oraz kompozycja farmaceutyczna PL213192B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0301259.8A GB0301259D0 (en) 2003-01-20 2003-01-20 Organic compounds

Publications (2)

Publication Number Publication Date
PL393385A1 true PL393385A1 (pl) 2011-03-14
PL213192B1 PL213192B1 (pl) 2013-01-31

Family

ID=9951448

Family Applications (2)

Application Number Title Priority Date Filing Date
PL376525A PL376525A1 (pl) 2003-01-20 2004-01-19 Sposób modyfikacji pokroju kryształów substancji leczniczej
PL393385A PL213192B1 (pl) 2003-01-20 2004-01-19 Sposób modyfikacji pokroju krysztalów substancji leczniczej, krysztaly mykofenolanu sodu i ich zastosowanie oraz kompozycja farmaceutyczna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL376525A PL376525A1 (pl) 2003-01-20 2004-01-19 Sposób modyfikacji pokroju kryształów substancji leczniczej

Country Status (31)

Country Link
US (3) US20060122265A1 (pl)
EP (2) EP2308471A1 (pl)
JP (1) JP4549976B2 (pl)
KR (5) KR100855149B1 (pl)
CN (2) CN101333201A (pl)
AR (2) AR043343A1 (pl)
AT (1) ATE546132T1 (pl)
AU (1) AU2004206731B2 (pl)
BR (1) BRPI0406827A (pl)
CA (2) CA2509796C (pl)
CL (1) CL2004000073A1 (pl)
CO (1) CO5580738A2 (pl)
CY (1) CY1112772T1 (pl)
DK (1) DK1592401T3 (pl)
EC (1) ECSP055918A (pl)
ES (1) ES2382035T3 (pl)
GB (1) GB0301259D0 (pl)
IL (1) IL169484A (pl)
MX (1) MXPA05007691A (pl)
MY (1) MY148297A (pl)
NO (1) NO20053846L (pl)
NZ (1) NZ541073A (pl)
PE (2) PE20040826A1 (pl)
PL (2) PL376525A1 (pl)
PT (1) PT1592401E (pl)
RU (1) RU2388757C2 (pl)
SG (1) SG155046A1 (pl)
SI (1) SI1592401T1 (pl)
TW (1) TWI325785B (pl)
WO (1) WO2004064806A2 (pl)
ZA (1) ZA200504442B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
MXPA06005659A (es) 2004-04-26 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de acido micofenolico y derivados de ester del mismo.
EP1740563A2 (en) 2004-04-27 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Mycophenolate mofetil impurity
US7439373B2 (en) 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
ES2391132T3 (es) * 2008-10-09 2012-11-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Uso de disolventes orgánicos en la granulación húmeda de moxifloxacino
CN101756958B (zh) * 2008-11-10 2011-07-20 鲁南制药集团股份有限公司 一种治疗关节炎的药物组合物及其制备方法
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EP2451797B1 (en) * 2009-07-10 2013-04-03 Janssen Pharmaceutica, N.V. CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
EA201270544A1 (ru) * 2009-10-13 2012-09-28 Тева Фармасьютикал Индастриз Лтд. Композиции с отсроченным высвобождением
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ, インコーポレイテッド (R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸およびその塩の調製のためのプロセス
SG10201506114UA (en) 2010-05-11 2015-09-29 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
EP2697218B1 (en) 2011-04-13 2016-05-25 Janssen Pharmaceutica NV Process for the preparation of compounds useful as inhibitors of sglt2
TWI582078B (zh) * 2013-01-23 2017-05-11 北京貝美拓新藥研發有限公司 抑制脯氨酸羥化酶活性的化合物的晶型及其應用
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
HUE049895T2 (hu) * 2015-12-21 2020-11-30 Janssen Pharmaceutica Nv Kristályosítási eljárás kanagliflozin hemihidrát kristályok elõállítására
MX2019009843A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
CN108727318A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 麦考酚酸的晶型物
CN108727317A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 一种麦考酚酸的晶型物
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN110922371B (zh) * 2019-12-27 2020-08-11 广东蓝宝制药有限公司 一种m2晶型麦考酚钠的制备方法
CN120208923A (zh) 2020-05-18 2025-06-27 诺华股份有限公司 Lnp023的结晶形式
KR20250013155A (ko) * 2022-05-31 2025-01-31 혼슈우 카가쿠고교 가부시키가이샤 4,4'-비스(1,1-비스(4-히드록시-3-메틸페닐)에틸)비페닐의 결정 및 그의 제조방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US158835A (en) * 1875-01-19 Improvement in mortising-tools
GB935432A (en) * 1958-05-29 1963-08-28 Secr Aviation Improvements in the manufacture of crystalline substances
US3187039A (en) * 1962-10-19 1965-06-01 Commercial Solvents Corp Method for changing the crystal habit of monosodium glutamate
US3183263A (en) * 1962-10-19 1965-05-11 Commercial Solvents Corp Method for changing the crystal habit of mono-sodium glutamate
US3352906A (en) * 1963-02-04 1967-11-14 Charles R Parkerson Habit modification and preparation of single crystal triglycine sulfate
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
US3770390A (en) * 1971-02-26 1973-11-06 Dow Chemical Co Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates
US4259239A (en) * 1980-04-21 1981-03-31 Allied Chemical Corporation Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam
IL60254A (en) 1980-06-08 1983-11-30 Yeda Res & Dev Resolution of amino acids
JPS5875194A (ja) * 1981-10-30 1983-05-06 株式会社日立製作所 マトリクス表示装置及び駆動方法
JPS59232916A (ja) * 1983-06-16 1984-12-27 Shiraishi Chuo Kenkyusho:Kk 針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物
IL77031A (en) 1985-11-12 1995-12-08 Yeda Res & Dev Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors
JPH0745359B2 (ja) 1987-12-25 1995-05-17 東レ株式会社 有機化合物結晶の製造方法
EP0582452B1 (en) * 1992-08-04 1998-10-14 Toda Kogyo Corp. Granulated particles for magnetic particles for magnetic recording and process for producing the same
JP3411038B2 (ja) 1993-09-15 2003-05-26 シンテックス(ユー・エス・エイ)・インコーポレイテッド ミコフェノール酸モフェチルの結晶質無水物およびその静注用製剤
JPH09209297A (ja) * 1996-01-26 1997-08-12 Nippon Paper Ind Co Ltd 艶消し軽量塗工紙及びその製造方法
KR100491274B1 (ko) * 1996-04-12 2005-09-05 노파르티스 아게 미코페놀레이트의장용코팅된약제조성물
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
FR2780403B3 (fr) * 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1592401A2 (en) 2005-11-09
MXPA05007691A (es) 2005-09-30
PE20040826A1 (es) 2004-12-23
SI1592401T1 (sl) 2012-05-31
IL169484A (en) 2016-03-31
PE20110276A1 (es) 2011-05-27
AU2004206731A1 (en) 2004-08-05
US8124795B2 (en) 2012-02-28
ES2382035T3 (es) 2012-06-04
AU2004206731A8 (en) 2004-08-05
JP2006515016A (ja) 2006-05-18
AR043343A1 (es) 2005-07-27
JP4549976B2 (ja) 2010-09-22
KR20090115821A (ko) 2009-11-06
GB0301259D0 (en) 2003-02-19
DK1592401T3 (da) 2012-05-21
KR20050096940A (ko) 2005-10-06
US20060122265A1 (en) 2006-06-08
NO20053846L (no) 2005-08-16
SG155046A1 (en) 2009-09-30
KR20070087181A (ko) 2007-08-27
CN1738605A (zh) 2006-02-22
PL376525A1 (pl) 2006-01-09
CL2004000073A1 (es) 2005-01-14
ATE546132T1 (de) 2012-03-15
ZA200504442B (en) 2006-02-22
EP1592401B1 (en) 2012-02-22
BRPI0406827A (pt) 2005-12-27
KR20090115898A (ko) 2009-11-09
MY148297A (en) 2013-03-29
WO2004064806A3 (en) 2004-10-28
CA2509796C (en) 2010-09-14
WO2004064806A2 (en) 2004-08-05
CO5580738A2 (es) 2005-11-30
RU2388757C2 (ru) 2010-05-10
KR101129105B1 (ko) 2012-04-12
IL169484A0 (en) 2007-07-04
PT1592401E (pt) 2012-05-10
ECSP055918A (es) 2005-11-22
US8008511B2 (en) 2011-08-30
HK1084874A1 (en) 2006-08-11
CA2509796A1 (en) 2004-08-05
AU2004206731B2 (en) 2008-03-20
PL213192B1 (pl) 2013-01-31
KR20100120321A (ko) 2010-11-15
CN100595199C (zh) 2010-03-24
KR100855149B1 (ko) 2008-08-28
CY1112772T1 (el) 2016-02-10
AR103711A2 (es) 2017-05-31
CN101333201A (zh) 2008-12-31
US20110288313A1 (en) 2011-11-24
US20090209639A1 (en) 2009-08-20
EP2308471A1 (en) 2011-04-13
RU2005126328A (ru) 2006-07-27
NZ541073A (en) 2008-12-24
CA2706900A1 (en) 2004-08-05
TWI325785B (en) 2010-06-11
TW200505505A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
PL393385A1 (pl) Sposób modyfikacji i rekrystalizacji pokroju kryształów substancji leczniczej, kryształy mykofenolanu sodu i ich zastosowanie oraz kompozycja farmaceutyczna
IL163831A0 (en) Derivatives of aminoindazoles, method of preparation and intermediates of the method as drugs pharmaceutical compounds containing
IL176236A (en) Heterocyclic compounds, pharmaceuticals containing them and their use in the preparation of drugs
AP2004003184A0 (en) Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same and methods for their use.
NO20033244D0 (no) Farmasöytisk sammensetning med redusert tendens for legemiddelkrystallisasjon
PL372084A1 (pl) Związek pochodnej 8-azaprostaglandyny i środek zawierający ten związek jako składnik aktywny
IL164798A0 (en) Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
PL375790A1 (pl) Nowe heterocykliczne pochodne fluoroglikozydu, leki zawierające te związki oraz ich zastosowanie
IL170690A0 (en) Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
IL164699A0 (en) Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
IL190218A0 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
NO20043733L (no) Aryl-5-tio-Β-D-glukopyranosid-derivater og legemidler for diabetes inneholdende de samme
IL166621A0 (en) Polymorph of n-methyl-n-(3-ä-3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5-alphaÜpyrimidin-7-ylüacetamide and pharmaceutical compositions containing the same
IL162765A (en) Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
EP1557415A4 (en) Heterocyclic compounds and antitumor agents containing them as an active ingredient
FR2838648B1 (fr) Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
ZA200506422B (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds
IL172733A0 (en) Diphenylpyridine derivatives, preparation and therapeutic application thereof
BRPI0312413A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos
IL163643A0 (en) Oxazolidinone derivatives, processes for their forpreparation, and pharmaceutical compositions containing them
AU2003218824A8 (en) Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them
ZA200602788B (en) Amidomethyl-substituted 2-(4-sulfonilamino)-3-hidroxy-3,4-dihydro-2H-chromen-6-YL-derivatives and drugs containing said compounds
HUP0500958A2 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them, therapeutic use thereof and pharmaceutical compositions containing them
PT2070914E (pt) Novos derivados antagonistas do receptor da vitronectina, procedimentos para a sua preparação, suas aplicações como medicamentos e as composições farmacêuticas que os contêm
EP1515960A4 (en) 2-THIOXOTHIAZOL DERIVATIVE, METHOD FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF